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PSA testing: When it’s useful, 
when it’s not
Routine PSA testing leads to more diagnoses of prostate 
cancer, but does not save lives. At least one group of men, 
however, may reap a small benefi t. 
PRACTICE CHANGER
Do not routinely screen all men over the 
age of 50 for prostate cancer with the pros-
tate-specifi c antigen (PSA) test. Consider 
screening men younger than 75 with no car-
diovascular or cancer risk factors—the only 
patient population for whom PSA testing ap-
pears to provide even a small benefi t.1,2 
STRENGTH OF RECOMMENDATION
B: Based on a meta-analysis of 6 randomized 
controlled trials (RCTs) with methodological 
limitations, and a post hoc analysis of a large 
RCT. 
Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate 
cancer: systematic review and meta-analysis of randomized controlled 
trials. BMJ. 2010;341:c4543.
Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality 
results from a randomized prostate cancer screening trial. J Clin Oncol. 
2011;29:355-361.
ILLUSTRATIVE CASES
A 65-year-old obese man with high blood 
pressure comes in for a complete physical and 
asks if he should have the “blood test for can-
cer.” He had a normal prostate specifi c anti-
gen (PSA) the last time he was tested, but that 
was 10 years ago. What should you tell him?
A 55-year-old man schedules a routine 
check-up and requests a PSA test. His last 
test, at age 50, was normal. The patient has 
no known medical problems and no family 
history of prostate cancer, and he exercises 
regularly and doesn’t smoke. How should you 
respond to his request for a PSA test? 
Prostate cancer is the second leading cause of cancer deaths among men in the United States, after lung cancer. 
One in 6 American men will be diagnosed 
with prostate cancer; for about 3% of them, 
the cancer will be fatal.3,4
Widespread testing without evidence 
of effi cacy
Th e PSA test was approved by the US Food 
and Drug Administration (FDA) in 1986.5 Its 
potential to detect early prostate cancer in the 
hope of decreasing morbidity and mortality 
led to widespread PSA screening in the 1990s, 
before data on the effi  cacy of routine screen-
ing existed. 
By 2002, only one low-quality RCT that 
compared screening with no screening had 
been published. Th e investigators conclud-
ed that screening resulted in lower mortal-
ity rates, but a subsequent (and superior) 
intention-to -treat analysis showed no 
mortality benefi t.6 Two large RCTs, both 
published in 2009, reported confl icting 
results.7,8 
❚ The European Randomized Study of 
Screening for Prostate Cancer (ERSPC) en-
rolled 182,000 men ages 50 to 74 years and 
randomized them to either PSA screen-
ing every 4 years or no screening. Prostate 
cancer-specifi c mortality was 20% lower for 
those in the screening group compared with 
the no-screening group; however, the abso-
lute risk reduction was only 0.71 deaths per 
1000 men.7 
CONTINUED
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❚ The US Prostate, Lung, Colorectal, 
Ovarian Cancer (PLCO) Screening Trial ran-
domized 77,000 men ages 55 to 74 years to 
either annual PSA and digital rectal exami-
nation (DRE) screening or usual care. After 
7 years of follow-up, no signifi cant diff erence 
was found in prostate cancer deaths or all-
cause mortality in the screening group vs the 
control group. It is important to note, how-
ever, that 52% of the men in the control group 
had ≥1 PSA screening during the study pe-
riod, which decreased the researchers’ ability 
to fully assess the benefi ts of screening.8 
PSA’s limitations 
and potential harmful effects
Th e PSA test’s signifi cant limitations and po-
tentially harmful eff ects counter the potential 
benefi ts of screening. About 75% of positive 
tests are false positives, which are associated 
with psychological harm in some men for up 
to a year after the test.6 In addition, diagnostic 
testing and treatment for what may be non-
life-threatening prostate cancer can cause 
harm, including erectile dysfunction (ED), 
urinary incontinence, bowel dysfunction, 
and death. Rates of ED and incontinence 18 
months after radical prostatectomy are an es-
timated 59.9% and 8.4%, respectively.9 
Do the benefi ts of PSA testing outweigh 
the harms—and for which men? Th e meta-
analysis and post hoc analysis detailed in this 
PURL help clear up the controversy.
STUDY SUMMARY
Widespread screening doesn’t save lives 
Djulbegovic et al examined 6 RCTs, includ-
ing the ERSPC and PLCO studies described 
earlier, that compared screening for prostate 
cancer (PSA with or without DRE) with no 
screening or usual care.1 Together, the stud-
ies included nearly 390,000 men ages 45 to 
80 years, and had 4 to 15 years of follow-up. 
Th e results showed that routine screening 
for prostate cancer had no statistically sig-
nifi cant eff ect on all-cause mortality (relative 
risk [RR]=0.99; 95% confi dence interval [CI], 
0.97-1.01), death from prostate cancer 
(RR=0.88; 95% CI, 0.71-1.09), or diagnosis 
of stage III or IV prostate cancer (RR=0.94; 
95% CI, 0.85-1.04). Routine screening did, 
however, increase the probability of being 
diagnosed with prostate cancer at any stage, 
especially at stage I. For every 1000 men 
screened, on average, 20 more cases of pros-
tate cancer were diagnosed. 
Healthy men may benefi t from screening
Crawford et al conducted a post hoc analysis 
of the PLCO trial, which had found no benefi t 
to annual PSA testing and serial DRE com-
pared with usual care for the general popula-
tion.2 Th eir analysis compared the mortality 
benefi ts (both prostate cancer–specifi c and 
overall) of annual PSA screening for healthy 
men with no or minimal comorbidities vs the 
mortality benefi ts for men with any risk factor 
for the 2 leading causes of death: cancer and 
cardiovascular disease.
Annual PSA testing yielded more 
diagnoses of prostate cancer in both healthy 
and at-risk men. Deaths from prostate cancer 
were infrequent in both groups, occurring in 
0.22% (164/73,378) of all participants. 
Men with ≥1 risk factor had similar pros-
tate cancer–specifi c deaths with both yearly 
screening and usual care (62 vs 42 deaths, ad-
justed hazard ratio [AHR]=1.43; 95% CI, 0.96-
2.11); their prostate cancer–specifi c mortality 
rate was 0.27% (95% CI, 0.21-0.34) and 0.19% 
(95% CI, 0.14-0.25), respectively. 
However, healthy men younger than 
75 years had fewer prostate cancer–specifi c 
deaths with annual PSA screenings (22 vs 38; 
AHR=0.56; 95% CI, 0.33-0.95; P=.03). Spe-
cifi cally, the prostate cancer mortality rate 
was 0.17% (95% CI, 0.11-0.25) in the group 
that received screening vs 0.31% (95% CI, 
0.22-0.42) in the usual care group. Th us, the 
absolute risk reduction for prostate cancer-
specifi c mortality in men without comorbidi-
ties who received yearly screening instead of 
usual care was 0.14% (0.31% vs 0.17%, P=.03), 
with a number needed to screen of 723 to pre-
vent one death from prostate cancer. Th ere was 
a non-signifi cant reduction in all-cause mor-
tality in the intervention group vs the control 
group (AHR=0.93; 95% CI, 0.86-1.02; P=.11). 
WHAT’S NEW
At best, screening has a small benefi t 
Th ese trials indicate that only a small group of 
About 75% of 
positive PSA 
tests are false 
positives. 
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Routine 
screening has no 
signifi cant effect 
on all-cause 
mortality, but 
does increase 
the probability 
of being 
diagnosed with 
prostate cancer.
men will potentially benefi t from PSA screen-
ing. Prior to this meta-analysis, a Cochrane 
review published in 2006 had concluded that 
there was insuffi  cient evidence to support or 
refute the routine use of mass screening for 
prostate cancer.10 Th e meta-analysis by Djul-
begovic et al, which included 4 additional tri-
als, 2 of them large, found no benefi t of PSA 
screening in reducing mortality from prostate 
cancer for the general population.1
Annual screening does appear to provide 
a small reduction in prostate cancer deaths 
but no signifi cant reduction in all-cause mor-
tality in men younger than age 75 who have 
no risk factors for cancer or cardiovascular 
disease.
CAVEATS
Study limitations, some unknowns
Th ese studies did not address whether cer-
tain groups at higher risk of developing pros-
tate cancer, such as African American men 
and those with a family history of prostate 
cancer, would benefi t from PSA screening. In 
addition, both of the studies detailed in this 
PURL had substantive weaknesses. 
Methodological limitations of the stud-
ies in the meta-analysis included the lack 
of intention-to-treat analysis and allocation 
concealment, which favors fi nding a benefi t 
for the screening arm, and PSA screening in 
the nonscreening arm, which biases the re-
sults toward not fi nding a screening benefi t 
that might exist. Despite these weaknesses, 
this meta-analysis brings together the best 
available evidence of the value of screening 
for prostate cancer.
In addition, there was no quantitative 
assessment of complication rates included 
in the meta-analysis. None of the 6 trials col-
lected data on the eff ect of screening or treat-
ment on participants’ quality of life.
In the post hoc study showing a benefi t 
for screening healthy men, the decrease in 
prostate cancer deaths was small in mag-
nitude, did not have an impact on all-cause 
mortality, and was of marginal statistical sig-
nifi cance. Although the data came from the 
largest multicenter study to date of prostate 
cancer screening, the results of a post hoc 
analysis of a single trial should be interpreted 
with caution. Th e study was initially designed 
to test the eff ect of screening on a general 
population. Whenever a study deviates from 
the original hypothesis to evaluate a subset 
of the study population, the investigators in-
crease the risk of fi nding a diff erence where 
none exists. Th us, it is possible that the fi nd-
ings of benefi t for healthy men may not truly 
be present.
What’s more, the risk factors identifi ed 
by the authors could be interpreted as arbi-
trary. Th ey included diverticulosis, which is 
not known to increase the likelihood of can-
cer or heart disease, as a risk factor. By the 
same token, smoking—a known risk factor 
for both cancer and cardiovascular disease—
was not addressed. Finally, potential harms 
associated with false-positive tests and pros-
tate cancer treatment were not addressed in 
these studies.
CHALLENGES TO IMPLEMENTATION
Old habits die hard
Clinicians have recommended PSA screening 
for men >50 years, and men have requested 
such screening, for more than 2 decades. 
Physicians often opt to order a PSA test rath-
er than to take the time to explain potential 
harms and benefi ts and listen to the patient’s 
thoughts and feelings about the value of 
screening. In addition, physicians who be-
lieve the lack of benefi t from screening does 
not apply to their patients will continue to 
order the PSA test. (See “Th e perils of PSA 
screening”  [editorial] on page 319.)
Patients may opt to continue to be 
screened although they have developed a risk 
factor for cardiovascular disease. Also, a de-
cision not to screen directly contradicts the 
recommendation of the American Urological 
Association, which calls for annual PSA test-
ing for asymptomatic men with a life expec-
tancy >10 years starting at 40 years of age.11 
Shared decision-making
Th e US Preventive Services Task Force 
(USPSTF) provides a basis for shared deci-
sion-making between physicians and pa-
tients concerning prostate cancer screening. 
Th e USPSTF states that there is insuffi  cient 
evidence to recommend for or against pros-
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tate cancer screening for the general male 
population younger than age 75 and recom-
mends against screening men age 75 and old-
er or those with a life expectancy of less than 
10 years.12
Decisions regarding PSA screening 
should be shared and documented for all men 
between the ages of 50 and 75 years. Advise 
patients with risk factors that the evidence 
shows little value and possible harm from 
screening. Tell healthier men that PSA testing 
appears to off er a small benefi t, at best.         JFP
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